ES2599781T3 - Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen - Google Patents
Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen Download PDFInfo
- Publication number
- ES2599781T3 ES2599781T3 ES10715912.1T ES10715912T ES2599781T3 ES 2599781 T3 ES2599781 T3 ES 2599781T3 ES 10715912 T ES10715912 T ES 10715912T ES 2599781 T3 ES2599781 T3 ES 2599781T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- cells
- amino acid
- zero
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 17
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title description 17
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title description 17
- 239000000203 mixture Substances 0.000 title description 11
- 230000003712 anti-aging effect Effects 0.000 title description 4
- 230000003213 activating effect Effects 0.000 title description 2
- 102000004196 processed proteins & peptides Human genes 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000004475 Arginine Substances 0.000 abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- -1 or equals zero Substances 0.000 abstract 1
- 150000003141 primary amines Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 210000002510 keratinocyte Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 102000005936 beta-Galactosidase Human genes 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108010004108 peptidylglutamylpeptide hydrolase Proteins 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000006315 carbonylation Effects 0.000 description 4
- 238000005810 carbonylation reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102400000827 Saposin-D Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- FOYHOBVZPWIGJM-KCHLEUMXSA-N (4s)-4-[[(2s)-4-methyl-2-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]-5-[(4-methyl-2-oxochromen-7-yl)amino]-5-oxopentanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 FOYHOBVZPWIGJM-KCHLEUMXSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000037012 chymotrypsin-like activity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0901614A FR2944018B1 (fr) | 2009-04-02 | 2009-04-02 | Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant |
| FR0901614 | 2009-04-02 | ||
| PCT/FR2010/000277 WO2010112710A2 (fr) | 2009-04-02 | 2010-04-01 | Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2599781T3 true ES2599781T3 (es) | 2017-02-03 |
Family
ID=41328482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10715912.1T Active ES2599781T3 (es) | 2009-04-02 | 2010-04-01 | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8530622B2 (enExample) |
| EP (1) | EP2414381B1 (enExample) |
| JP (1) | JP5728466B2 (enExample) |
| CN (1) | CN102428095B (enExample) |
| ES (1) | ES2599781T3 (enExample) |
| FR (1) | FR2944018B1 (enExample) |
| WO (1) | WO2010112710A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2514403A1 (en) * | 2011-04-20 | 2012-10-24 | Coty Germany GmbH | Cosmetic composition for increasing the collagen synthesis in the skin cells |
| EP2810934A1 (en) | 2013-06-09 | 2014-12-10 | Symrise AG | New succinate derivatives |
| CN108350030B (zh) * | 2015-09-10 | 2022-12-13 | 汉阳大学校产学协力团 | 皮肤可渗透肽及其使用方法 |
| WO2018154080A1 (en) * | 2017-02-24 | 2018-08-30 | Lipotrue, S.L. | Peptides and compositions for use in cosmetics |
| ES3032335T3 (en) * | 2019-12-04 | 2025-07-17 | Lipotrue S L | Peptides and compositions for use in cosmetics and medicine |
| JP2022012379A (ja) * | 2020-07-01 | 2022-01-17 | 国立大学法人富山大学 | ユビキチン－プロテアソーム系の活性化剤、およびその利用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2704754B1 (fr) | 1993-05-07 | 1995-06-30 | Oreal | Utilisation d'un alkyle ester de glutathion dans une composition cosmetique ou dermatologique destinee au traitement par voie topique du vieillissement cutane. |
| WO2000004042A1 (fr) * | 1998-07-15 | 2000-01-27 | Sumitomo Electric Industries, Ltd. | Composes peptidiques |
| FR2822701B1 (fr) | 2001-04-03 | 2005-03-18 | Lvmh Rech | Utilisation d'un extrait d'algue phaeodactylum comme agent cosmetique favorisant l'activite du proteasome des cellules de la peau et composition cosmetique le contenant |
| WO2003055448A2 (en) * | 2001-12-21 | 2003-07-10 | Achillion Pharmaceuticals, Inc. | Antifungal compositions |
| US20050282747A1 (en) | 2003-10-01 | 2005-12-22 | The Research Foundation Of State University Of New York At Stony Brook | Methods and compositions for wound healing |
| FR2864085B1 (fr) * | 2003-12-18 | 2010-09-17 | Centre Nat Rech Scient | Nouveaux modulateurs du proteasome |
| FR2869228B1 (fr) | 2004-04-21 | 2008-09-05 | Vincience Sa | Utilisation d'un hydrolysat de proteines de cruciferes en tant qu'agent depigmentant dans ou pour une composition cosmetique et/ou pharmaceutique |
| US7919468B2 (en) | 2005-04-07 | 2011-04-05 | Centre National De La Recherche Scientifique (C.N.R.S.) | Compounds useful as modulators of the proteasome activity |
| JP3914244B2 (ja) | 2005-10-03 | 2007-05-16 | 株式会社ファンケル | 異常タンパク質除去用組成物 |
| FR2898808B1 (fr) | 2006-03-27 | 2008-05-02 | Biotechmarine Soc Par Actions | "principe actif cosmetique compose de ferrulate d'arginine et d'un extrait de microalgue et ses utilisations". |
| BRPI0712073B8 (pt) * | 2006-05-17 | 2021-05-25 | Hoffmann La Roche | ácido nucléico para produção de um polipeptídio ou proteína heteróloga |
| FR2903903B1 (fr) | 2006-07-18 | 2008-08-29 | Expanscience Laboratoires Sa | Utilisation d'un hydrolysat de proteines de riz en tant que principe actif pigmentant |
| WO2008015343A2 (fr) | 2006-08-03 | 2008-02-07 | Societe D'extraction Des Principes Actifs Sa (Vincience) | Utilisation d'un extrait de levure en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes |
| FR2904552B1 (fr) | 2006-08-03 | 2012-09-21 | Soc Extraction Principes Actif | Utilisation d'un extrait de levure en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes |
| FR2915378B1 (fr) | 2007-04-27 | 2009-08-21 | Vincience Sa | Utilisation d'un principe actif issu du soja (glycine max l.) pour preparer une composition destinee a proteger les mitochondries |
| FR2915379B1 (fr) | 2007-04-27 | 2012-07-13 | Vincience | Utilisation d'un principe actif issu du riz (oryza sativa l) pour preparer une composition destinee a proteger les mitochondries |
| FR2915383B1 (fr) | 2007-04-27 | 2010-01-15 | Vincience | Utilisation d'un principe actif issu du riz (oryza sativa l.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs. |
| FR2915380B1 (fr) | 2007-04-27 | 2012-06-08 | Vincience | Utilisateur d'un principe actif issu du riz (oryza sativa l) pour preparer une composition destinee a activer le cytochrome c |
| FR2915382B1 (fr) | 2007-04-27 | 2012-06-01 | Vincience | Utilisation d'un principe actif issu du mais (zea mays l) pour preparer une composition destinee a activer le cytochrome c |
| FR2915381B1 (fr) | 2007-04-27 | 2012-06-08 | Vincience | Utilisation d'un principe actif issu du soja (glycine max l) pour preparer une composition destinee a activer le cytochrome c |
| FR2915384B1 (fr) | 2007-04-27 | 2010-01-15 | Vincience | Utilisation d'un principe actif issu du soja (glycine maxl.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs. |
-
2009
- 2009-04-02 FR FR0901614A patent/FR2944018B1/fr not_active Expired - Fee Related
-
2010
- 2010-04-01 WO PCT/FR2010/000277 patent/WO2010112710A2/fr not_active Ceased
- 2010-04-01 US US13/262,305 patent/US8530622B2/en active Active
- 2010-04-01 ES ES10715912.1T patent/ES2599781T3/es active Active
- 2010-04-01 JP JP2012502731A patent/JP5728466B2/ja not_active Expired - Fee Related
- 2010-04-01 CN CN201080021998.3A patent/CN102428095B/zh not_active Expired - Fee Related
- 2010-04-01 EP EP10715912.1A patent/EP2414381B1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8530622B2 (en) | 2013-09-10 |
| FR2944018A1 (fr) | 2010-10-08 |
| JP2012522757A (ja) | 2012-09-27 |
| CN102428095A (zh) | 2012-04-25 |
| EP2414381A2 (fr) | 2012-02-08 |
| EP2414381B1 (fr) | 2016-08-10 |
| FR2944018B1 (fr) | 2012-03-09 |
| WO2010112710A2 (fr) | 2010-10-07 |
| US20120040912A1 (en) | 2012-02-16 |
| CN102428095B (zh) | 2015-04-08 |
| WO2010112710A3 (fr) | 2010-11-25 |
| JP5728466B2 (ja) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | ADAMDEC1 promotes skin inflammation in rosacea via modulating the polarization of M1 macrophages | |
| Mah et al. | Elevated CD26 expression by skin fibroblasts distinguishes a profibrotic phenotype involved in scar formation compared to gingival fibroblasts | |
| ES2537346T3 (es) | Hidrolizados peptídicos activadores del proteasoma y composiciones que los contienen | |
| ES2786041T3 (es) | Uso cosmético de polipéptidos de tipo lacritina | |
| PE20010693A1 (es) | Metodo para la determinacion de actividad alfa-secretasa sobre la app | |
| Sela et al. | Degradation of collagen‐guided tissue regeneration membranes by proteolytic enzymes of Porphyromonas gingivalis and its inhibition by antibacterial agents | |
| CN102428095B (zh) | 新型蛋白酶体激活性抗衰老肽及含有所述肽的组合物 | |
| US20190234939A1 (en) | Juvenile Atopic Dermatitis Models | |
| ES2498674T3 (es) | Métodos para medir la viabilidad celular sin usar células de control | |
| ES2532545T3 (es) | Nuevos péptidos que intervienen en la vía de señalización de SCF c-Kit y composiciones que los comprenden | |
| US20120027703A1 (en) | Novel proteasome-activating anti-aging peptides and compositions containing same | |
| US20180161262A1 (en) | Cosmetic Method and Dermatological Topical Agent for Use Therein, Migration Imparting Agent, and Method for Screening Components for Use in Cosmetic Method for Improving Skin State | |
| Holtz | In vitro methods to screen materials for anti-aging effects | |
| JP5858482B2 (ja) | スルビビンを調節する新規の抗加齢ペプチドおよびこれを含む組成物 | |
| Prokopov et al. | Effect of a hyaluronic acid‐based mesotherapeutic injectable on the gene expression of CLOCK and Klotho proteins, and environmentally induced oxidative stress in human skin cells | |
| CN107405278B (zh) | 序列为his-d-trp-ala-trp-d-phe-lys-nh2的肽用于减少或延缓细胞衰老的出现和皮肤老化的迹象的用途 | |
| TWI586358B (zh) | Extraction of bleomycin extract, angelica extract, cork extract, wild sesame extract, rosemary extract, benzenesulfonyl GABA and erythritol for the manufacture of bleomycin hydrolyzate production accelerator | |
| Cheong et al. | Spatiotemporal‐controlled reporter for cell‐surface proteolytic enzyme activity visualization | |
| Kato et al. | Inhibition of sea urchin fertilization by jaspisin, a specific inhibitor of matrix metalloendoproteinase | |
| CN102947323B (zh) | 新的胱天蛋白酶-14激活肽及包含所述激活肽的组合物 | |
| JP7474736B2 (ja) | 白斑の予防又は改善剤の評価又は選択方法 | |
| JP7665379B2 (ja) | 乳頭突起形成促進剤のスクリーニング方法および、乳頭突起形成促進剤 | |
| Yokota et al. | Effects of proteasome inhibitors on fertilization of the sea urchin Anthocidaris crassispina | |
| Imbert et al. | Maintenance of the ubiquitin–proteasome system activity correlates with visible skin benefits | |
| Cressman | Investigating Mechanisms of Impaired Mineralization Due to Deficient Spermine Synthase Activity |